Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that it has commenced an underwritten public offering of $150 million of its common ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE